{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T09:18:29Z","timestamp":1649150309981},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1016\/j.ijantimicag.2004.12.002","type":"journal-article","created":{"date-parts":[[2005,2,17]],"date-time":"2005-02-17T23:09:22Z","timestamp":1108681762000},"page":"237-246","source":"Crossref","is-referenced-by-count":2,"title":["Bacteriological efficacy of 5-day therapy with telithromycin in acute maxillary sinusitis"],"prefix":"10.1016","volume":"25","author":[{"given":"P.","family":"Buchanan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Roos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Tellier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Rangaraju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2004.12.002_bib1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00019048-199705000-00002","article-title":"IDCP guidelines: management of upper respiratory tract infections","volume":"6","author":"Bartlett","year":"1997","journal-title":"Infect Dis Clin Pract"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00000441-199807000-00003","article-title":"Microbiology of acute and chronic sinusitis in children and adults","volume":"316","author":"Wald","year":"1998","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib3","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0194-5998(00)70051-9","article-title":"Endoscopically guided sinonasal cultures: a direct comparison with maxillary sinus aspirate cultures","volume":"122","author":"Vogan","year":"2000","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"Suppl. 9A","key":"10.1016\/j.ijantimicag.2004.12.002_bib4","first-page":"10S","article-title":"Epidemiology of sinusitis in the primary care setting: results from the 1999\u20132000 respiratory surveillance program","volume":"111","author":"Sokol","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib5","first-page":"2","article-title":"Medical management of acute bacterial sinusitis: recommendations of a clinical advisory committee on pediatric and adult sinusitis","volume":"182","author":"Brooks","year":"2000","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib6","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1067\/mhn.2000.107873","article-title":"Antimicrobial treatment guidelines for acute bacterial rhinosinusitis","volume":"123","year":"2000","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2004.12.002_bib7","first-page":"29","article-title":"Considerations in diagnosis and treatment of sinusitis","volume":"3","author":"Sokol","year":"1999","journal-title":"Antibiot Clin"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib8","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1136\/bmj.309.6966.1415","article-title":"Diagnosis and management of sinusitis","volume":"201","author":"Evans","year":"1994","journal-title":"BMJ"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2004.12.002_bib9","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1086\/324525","article-title":"Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST surveillance program","volume":"34","author":"Thornsberry","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"Suppl. A","key":"10.1016\/j.ijantimicag.2004.12.002_bib10","first-page":"3","article-title":"Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective resistant organism tracking and epidemiology for the ketolide telithromycin","volume":"44","author":"Felmingham","year":"2002","journal-title":"J Infect"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2004.12.002_bib11","first-page":"25A","article-title":"Short courses of antibiotic in acute otitis media and sinusitis infections","volume":"28","author":"Pichicero","year":"2000","journal-title":"J Int Med Res"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jama.279.5.365","article-title":"Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae","volume":"279","author":"Guillemot","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib13","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1128\/AAC.45.6.1721-1729.2001","article-title":"Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999\u20132000, including a comparison of resistance rates since 1994\u20131995","volume":"45","author":"Doern","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 9A","key":"10.1016\/j.ijantimicag.2004.12.002_bib14","doi-asserted-by":"crossref","first-page":"4S","DOI":"10.1016\/S0002-9343(01)01025-7","article-title":"Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment","volume":"111","author":"Pfaller","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib15","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1128\/AAC.45.6.1688-1692.2001","article-title":"In vivo efficacy of the new ketolide telithromycin (HMR 3647) in murine infection models","volume":"45","author":"Bonnefoy","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0732-8893(99)00053-X","article-title":"In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis","volume":"35","author":"Hoban","year":"1999","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib17","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1128\/AAC.42.4.945","article-title":"Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin\u2013dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin)","volume":"42","author":"Barry","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1128\/AAC.45.3.789-793.2001","article-title":"In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species","volume":"45","author":"Jalava","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0924-8579(01)00346-6","article-title":"Activity of the ketolide telithromycin (HMR 3647) against erythromycin-susceptible and -resistant pneumococci isolated in the UK","volume":"18","author":"Johnson","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib20","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1128\/AAC.45.9.2427-2431.2001","article-title":"In vitro activity of telithromycin against Spanish Streptococcus pneumoniae isolates with characterized macrolide resistance mechanisms","volume":"45","author":"Morosini","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib21","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1128\/AAC.42.3.624","article-title":"Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents","volume":"42","author":"Pankuch","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib22","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/jac\/44.4.445","article-title":"In vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and beta-haemolytic streptococci","volume":"44","author":"Wootton","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib23","unstructured":"Felmingham D, Harding I. Telithromycin is highly active against clinical isolates of Streptococcus pneumoniae collected in the PROTEKT study, irresepective of penicillin, macrolide or fluoroquinolone resistance. Poster P-1253 presented at the 11th European Congress of Clinical Microbiology and Infectious Diseases, 1\u20134 April 2001, Istanbul, Turkey."},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0732-8893(98)00022-4","article-title":"Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains","volume":"31","author":"Biedenbach","year":"1998","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib25","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1128\/AAC.44.2.414-417.2000","article-title":"In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae","volume":"44","author":"Davies","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib26","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2165\/00003495-200161060-00016","article-title":"Telithromycin","volume":"61","author":"Barman Balfour","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib27","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/194589240301700610","article-title":"Telithromycin vs cefuroxime axetil in acute maxillary sinusitis","volume":"17","author":"Buchanan","year":"2003","journal-title":"Am J Rhinol"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib28","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000057670","article-title":"Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis","volume":"48","author":"Roos","year":"2002","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib29","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1177\/014556130308200812","article-title":"Efficacy and tolerability of the ketolide telithromycin (HMR 3647) for 5 or 10 days vs amoxicillin\/clavulanic acid for 10 days in the treatment of acute maxillary sinusitis (AMS) in adults","volume":"82","author":"Luterman","year":"2003","journal-title":"Ear Nose Throat J"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib30","unstructured":"National Committee for Clinical Laboratory Standards (NCCLS). Performance Standards for Antimicrobial Susceptibility Testing, 14th informational supplement. NCCLS Document M100-S14. Wayne, PA: NCCLS; 2004."},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2004.12.002_bib31","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1093\/clind\/15.Supplement_1.S62","article-title":"Evaluation of new anti-infective drugs for the treatment of respiratory tract infections","volume":"15","author":"Chow","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib32","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1128\/AAC.41.7.1517","article-title":"Comparative effectiveness and safety of cefdinir and amoxicillin\u2013clavulanate in treatment of acute community-acquired bacterial sinusitis","volume":"41","author":"Gwaltney","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib33","first-page":"3","article-title":"Ciprofloxacin versus cefuroxime axetil in the treatment of acute bacterial sinusitis","volume":"28","author":"Johnson","year":"1999","journal-title":"J Otolaryngol"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib34","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/rmed.1999.0769","article-title":"A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults","volume":"94","author":"Siegert","year":"2000","journal-title":"Respir Med"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib35","unstructured":"Miyamoto N, Murakami S, Yajin K, et al. Pharmacokinetic study of a new ketolide antimicrobial telithromycin (HMR 3647) in otorhinolaryngology [abstract 2144 and poster]. In: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 17\u201320 September 2000. Toronto, Canada. Washington DC: American Society for Microbiology; 2000. p. 32."},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib36","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1365-2958.2000.01841.x","article-title":"Macrolide\u2013ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA","volume":"36","author":"Douthwaite","year":"2000","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib37","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1046\/j.1365-2958.1999.01202.x","article-title":"The macrolide\u2013ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA","volume":"31","author":"Hansen","year":"1999","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib38","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1046\/j.1365-2958.1999.01203.x","article-title":"A ketolide resistance mutation in domain II of 23S rRNA reveals the proximity of hairpin 35 to the peptidyl transferase centre","volume":"31","author":"Xiong","year":"1999","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib39","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1086\/341978","article-title":"Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae","volume":"35","author":"Lonks","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib40","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1001\/jama.286.15.1857","article-title":"Macrolide resistance among invasive Streptococcus pneumoniae isolates","volume":"286","author":"Hyde","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib41","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1128\/AAC.45.1.170-175.2001","article-title":"Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses","volume":"45","author":"Namour","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib42","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/jac\/dkf046","article-title":"Patient compliance with antibiotic treatment for respiratory tract infections","volume":"49","author":"Kardas","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib43","first-page":"266","article-title":"Overview of issues related to medical compliance with implications for the outpatient management of infectious diseases","volume":"3","author":"Sclar","year":"1994","journal-title":"Infect Agents Dis"},{"key":"10.1016\/j.ijantimicag.2004.12.002_bib44","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compliance","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin Ther"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857905000129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857905000129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T20:44:05Z","timestamp":1586119445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857905000129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0924857905000129"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2004.12.002","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}